Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Antoine TE, Park PJ, Shukla D.

Rev Med Virol. 2013 May;23(3):194-208. doi: 10.1002/rmv.1740. Epub 2013 Feb 26. Review.

2.

Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread.

Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD.

J Virol. 2011 May;85(9):4386-98. doi: 10.1128/JVI.01492-10. Epub 2011 Feb 9.

3.

Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen and NPPB.

Zheng K, Chen M, Xiang Y, Ma K, Jin F, Wang X, Wang X, Wang S, Wang Y.

Biochem Biophys Res Commun. 2014 Apr 18;446(4):990-6. doi: 10.1016/j.bbrc.2014.03.050. Epub 2014 Mar 19.

PMID:
24657267
4.

Inhibition of myosin light chain kinase can be targeted for the development of new therapies against herpes simplex virus type-1 infection.

Antoine TE, Shukla D.

Antivir Ther. 2014;19(1):15-29. doi: 10.3851/IMP2661. Epub 2013 Jun 28.

PMID:
23813409
5.

Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo.

Tiwari V, Liu J, Valyi-Nagy T, Shukla D.

J Biol Chem. 2011 Jul 15;286(28):25406-15. doi: 10.1074/jbc.M110.201103. Epub 2011 May 19.

6.

Houttuynia cordata targets the beginning stage of herpes simplex virus infection.

Hung PY, Ho BC, Lee SY, Chang SY, Kao CL, Lee SS, Lee CN.

PLoS One. 2015 Feb 2;10(2):e0115475. doi: 10.1371/journal.pone.0115475. eCollection 2015.

7.

Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1.

Arii J, Goto H, Suenaga T, Oyama M, Kozuka-Hata H, Imai T, Minowa A, Akashi H, Arase H, Kawaoka Y, Kawaguchi Y.

Nature. 2010 Oct 14;467(7317):859-62. doi: 10.1038/nature09420.

PMID:
20944748
8.

Anti-HSV activity of digitoxin and its possible mechanisms.

Su CT, Hsu JT, Hsieh HP, Lin PH, Chen TC, Kao CL, Lee CN, Chang SY.

Antiviral Res. 2008 Jul;79(1):62-70. doi: 10.1016/j.antiviral.2008.01.156. Epub 2008 Feb 21.

PMID:
18353452
9.

Contortrostatin, a homodimeric disintegrin isolated from snake venom inhibits herpes simplex virus entry and cell fusion.

Hubbard S, Choudhary S, Maus E, Shukla D, Swenson S, Markland FS Jr, Tiwari V.

Antivir Ther. 2012;17(7):1319-26. doi: 10.3851/IMP2291. Epub 2012 Aug 8.

PMID:
22875654
10.

Exploiting herpes simplex virus entry for novel therapeutics.

Hadigal S, Shukla D.

Viruses. 2013 Jun 10;5(6):1447-65. doi: 10.3390/v5061447. Review.

11.

A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion.

Tiwari V, Shukla SY, Shukla D.

Antiviral Res. 2009 Oct;84(1):67-75. doi: 10.1016/j.antiviral.2009.07.014. Epub 2009 Aug 7.

12.

Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells.

Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ.

Antiviral Res. 2006 Dec;72(3):242-51. Epub 2006 Jul 14.

PMID:
16876885
13.

Dendrimers functionalized with membrane-interacting peptides for viral inhibition.

Tarallo R, Carberry TP, Falanga A, Vitiello M, Galdiero S, Galdiero M, Weck M.

Int J Nanomedicine. 2013;8:521-34. doi: 10.2147/IJN.S37739. Epub 2013 Feb 5.

14.

Herpes simplex virus internalization into epithelial cells requires Na+/H+ exchangers and p21-activated kinases but neither clathrin- nor caveolin-mediated endocytosis.

Devadas D, Koithan T, Diestel R, Prank U, Sodeik B, Döhner K.

J Virol. 2014 Nov;88(22):13378-95. doi: 10.1128/JVI.03631-13. Epub 2014 Sep 10.

15.

The amino terminus of herpes simplex virus 1 glycoprotein K is required for virion entry via the paired immunoglobulin-like type-2 receptor alpha.

Chowdhury S, Chouljenko VN, Naderi M, Kousoulas KG.

J Virol. 2013 Mar;87(6):3305-13. doi: 10.1128/JVI.02982-12. Epub 2013 Jan 9.

16.

A Functional Interaction between Herpes Simplex Virus 1 Glycoprotein gH/gL Domains I and II and gD Is Defined by Using Alphaherpesvirus gH and gL Chimeras.

Fan Q, Longnecker R, Connolly SA.

J Virol. 2015 Jul;89(14):7159-69. doi: 10.1128/JVI.00740-15. Epub 2015 Apr 29.

17.

A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells.

Ali MM, Karasneh GA, Jarding MJ, Tiwari V, Shukla D.

J Virol. 2012 Jun;86(12):6434-43. doi: 10.1128/JVI.00433-12. Epub 2012 Apr 4.

18.

Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: implications for the development of entry-based antiviral therapy.

Jaishankar D, Yakoub AM, Bogdanov A, Valyi-Nagy T, Shukla D.

J Virol. 2015 Feb;89(3):1932-8. doi: 10.1128/JVI.02979-14. Epub 2014 Nov 26.

19.

Herpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96.

Schwartz JA, Lium EK, Silverstein SJ.

J Virol. 2001 May;75(9):4117-28.

20.

Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection.

Antoine TE, Mishra YK, Trigilio J, Tiwari V, Adelung R, Shukla D.

Antiviral Res. 2012 Dec;96(3):363-75. doi: 10.1016/j.antiviral.2012.09.020. Epub 2012 Oct 6.

Supplemental Content

Support Center